Variability of prasugrel antiplatelet effect in patients with acute coronary syndrome ABSTRACT Background. Many reports have demonstrated excessive variability in response to clopidogrel, the most
Introduction
Platelet activation and aggregation play a pivotal role in the pathophysiology of acute coronary syndromes (ACS) [1] . Dual antiplatelet therapy (DAT) with aspirin and one of the platelet P2Y12 receptor antagonists reduces the risk of thrombotic events. This treatment is recommended in the management of patients with ACS and in patients after stent implantation [2] [3] [4] . Many reports have demonstrated excessive variability in response to clopidogrel, the most commonly used P2Y12 receptor antagonist, with a substantial rate of high on-treatment platelet reactivity (HTPR) [5] [6] [7] [8] . Subjects with HTPR undergoing percutaneous coronary intervention (PCI) were shown to be at increased risk of cardiovascular (CV) events [6, 9] . Prasugrel is a new P2Y12 inhibitor that provides greater and faster platelet inhibition. It was shown to reduce CV events more effectively than clopidogrel in ACS patients undergoing PCI [10] [11] [12] .
The aim of this study was to evaluate the inter-individual and intra-individual variability of prasugrel antiplatelet activity in patients with ACS treated with PCI.
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Materials and methods

Study design and population
This study was designed as a prospective, single--center, non-randomized, observational trial. Forty-two consecutive patients admitted to the Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz and treated with PCI for ACS were prospectively recruited into the study between 24 July 2013 and 16 May 2014. The enrollment during first two days of hospitalization.
Study exclusion criteria included: -age under 18 or over 75 years; -history of ischemic stroke or transient ischemic attack; -body weight below 60 kilograms; -severe liver failure (Child-Pugh class C); -need for prolonged use of oral anticoagulant therapy, heparin or fondaparinux; -bleeding disorders (including thrombocytopenia < 100 × 10 3 /µL); -anemia (defined as hemoglobin concentration < 10.0 g/dL); -active inflammation; -cardiogenic shock on admission; -heart failure class III and IV according to the New York Heart Association (NYHA) classification; -any contraindication to prasugrel due to increased risk of bleeding according to the attending physician. All participants provided written informed consent. The study was approved by the Ethical Committee of the Nicolaus Copernicus University in accordance with the Declaration of Helsinki.
Pharmacotherapy
Directly after enrollment for the study patients were treated with a loading dose (60 mg) of prasugrel regardless of earlier antiplatelet treatment. The day of study inclusion was marked as "day 0". Throughout the following hospitalization period prasugrel was continued in a single daily dose of 10 mg administered at 8.00 a.m. Concomitant medication in all patients included aspirin (300 mg loading dose given immediately after establishing ACS diagnosis, followed by a 75 mg maintenance dose once daily), ramipril and bisoprolol in doses adjusted for resting heart rate and blood pressure, and atorvastatin (40 mg). All medications were administered at 8.00 a.m., except for atorvastatin, which was administered at 8.00 p.m. Gastroprotection with pantoprazole was given at the discretion of the attending physician.
Measurement of platelet aggregation
Blood samples for platelet function testing were collected at 3 time points: on the 3 rd day of the maintenance treatment with 10 mg daily prasugrel dose (called "day 3") at 8:00 a.m. (before prasugrel administration), on "day 3" at 4:00 p.m. (8 h after the previous dose of prasugrel) and on the 4 th day (called "day 4") at 8:00 a.m. (prior to prasugrel administration). Prasugrel dosing regimen and timing of platelet testing are presented in Table 1 .
Blood samples for platelet reactivity (PR) assessment were drawn through a short venous catheter inserted into a forearm vein. Platelet function testing was performed with the VeryfyNow (Accumetrics Inc, San Diego, CA) point-of-care P2Y12 function assay. The results are reported in P2Y12 reaction unit (PRU). According to the previous studies, PRU > 208 was considered HTPR associated with an increased risk of thrombotic events [13, 14] , while PRU < 30 PRU was considered LTPR (low on-treatment platelet reactivity) associated with an increased risk of bleeding complications [14] [15] [16] . The ANOVA Friedman test confirmed a significant heterogeneity in the platelet reactivity assessed at different sampling points (p < 0.00001; Fig. 1 ). Intra-individual platelet aggregation variability is also well depicted when the measurements of individual patients are followed (Fig. 2) . All study participants were effectively treated with prasugrel during hospitalization (PRU < 208 at each measurement point). LTPR was observed in 77 out of 126 measurements (61.1%). The highest prevalence of LTPR was found on day 3 at 4:00 p.m. (80.9%), while the lowest prevalence of LTPR was seen on day 4 at 8.00 a.m. (42.9%) (Fig. 3) . In 15 subjects (35.7%) LTPR was observed at all three measurement points. When this subset of patients was compared with subjects who had at least one platelet aggregation measurement within therapeutic range, a statistically higher percentage of active smokers was found in the persistent LTPR group (73. 
Statistical analysis
Results
The baseline characteristics of the study population are presented in Table 2 . We observed high inter-individual and intra-individual variability of platelet reactivity on prasugrel. Inter-individual variability, especially at the morning sampling points, is well reflected by broad interquartile (day 3: 4.0-40.0; day 4: 6.0-55.0) and non-outlier ranges (day 3: 0.0-93.0; day 4:1.0-127.0) (Fig. 1) . In contrast, in the afternoon the dispersion of the results of platelet reactivity assessment markedly decreased (3.0-14.0 and 0.0-25.0, respectively).
High intra-individual variability was reflected by huge differences in the platelet reactivity measure- 3) . Interestingly, the persistent LTPR subset of patients comprised only men, while all 4 women participating in the study had at least one platelet reactivity measurement within normal range. This difference however was not statistically significant, which may be due to the small representation of women in our study. Despite generally high variability in diurnal and dayto-day variations in platelet reactivity observed in our study we found 10 patients (23.8%) with fluctuations in VeryfyNow P2Y12 assay results below 5 PRU. Patients with the stable platelet function measurements significantly more often were active smokers (80.0 v. 43.8%; p = 0.04) and displayed tendencies for lower prevalence of hypertension (30.0 v. 62.5%; p = 0.07) and diabetes (0.0 v. 34.4%; p = 0.08) (Tab. 4). All 4 women were in the higher PR fluctuation group, however this difference in gender distribution was statistically insignificant.
Platelet reactivity assessed with the VeryfyNow P2Y12 assay at each sampling point was unrelated to platelet count or mean platelet volume.
Discussion
Efficient and stable platelet inhibition is the cornerstone of the treatment for patients with ACS and/or undergoing PCI. Prasugrel provides a more potent and stable antiplatelet effect when compared with clopidogrel [17, 18] . However, the main finding of our study is the relatively high inter-individual and intra-individual variability of platelet reactivity as assessed with the VeryfyNow P2Y12 assay among patients treated with a maintenance dose of prasugrel in the stable phase of ACS (Fig. 1, Fig. 2 ). Taking into account the relatively small population included in our study, significant differences of diurnal and day-to-day aggregation proved the existence of substantial variability. However, the analysis of data presented in Figure 2 leads to a conclusion that even with the prominent intra-individual differences in aggregation there is a subgroup of patients presenting a stable and relatively low level of platelet reactivity. Further analysis revealed that 10 patients with low PR fluctuations, below 5 PRU, more often were active smokers. Moreover, those patients tended to have a lower prevalence of diabetes mellitus and hypertension (Tab. 4).
Diabetes mellitus is associated with a chronic inflammatory state promoting platelets hyperactivity [19, 20] . Several studies showed resistance to a conventional antiplatelet therapy with aspirin and clopidogrel in diabetic patients [2, 20] . Prasugrel has been proven to be more effective than clopidogrel in both diabetic and non-diabetic subjects [21] . This pharmacodynamic effectiveness translated into a better clinical outcome in patients treated with prasugrel compared with clopidogrel in the TRITON-TIMI 38 study [10] . The composite ischemic event rate with prasugrel was diminished by 14% in non-diabetic patients, by 26% in non-insulin--treated diabetics, and by 37% in those treated with insulin [22] .
Despite superior antiplatelet potency of prasugrel its effect remains suboptimal in some subsets of patient. Diabetes is one of the strongest factors of high on-prasugrel platelet reactivity [23, 24] . Interestingly, in our population none of 11 diabetic patients displayed low PRU fluctuation. This suggests that diabetes is a risk factor not only for HTPR, but also for higher intra-individual variability.
Hypertension was also identified as a risk factor of aspirin and clopidogrel resistance in some studies [25, 26] . Recently, Verdoia et al. showed that hypertension may also be a risk factor for ticagrelor non-responsiveness. Among other risk factors, hypertension was significantly associated with high platelet reactivity in the univariate analysis. However, age ≥ 70 years, concomitant therapy with beta-blockers and platelets count were the only independent predictors of high on-ticagrelor platelet reactivity in the multivariate model [27] . Also retrospective analysis conducted by Bae et al. and a recent registry of PCI-treated patients did not indicate hypertension as a factor of high on-prasugrel platelet reactivity [23, 24] . In our study, a tendency for lower hypertension prevalence in the stable PR subset of patients was revealed, suggesting that hypertension might cause some variability in antiplatelet response.
It is a well-known fact that antiplatelet efficacy of clopidogrel is higher in smokers than in non-smokers. In a study conducted in 377 patients with coronary artery disease who had undergone PCI and were treated with clopidogrel, significantly lower PR was found in smokers. An association between smoking and antiplatelet activity was also confirmed with the multivariate analysis [28] . Moreover, the clinical benefit of clopidogrel in preventing cardiovascular events was greater in smokers than in non-smokers, a phenomenon termed the "smoker's paradox" [29, 30] . The explanation for this observation is cytochrome P 450 (CYP) 1A2 and 2B6 induction by cigarette smoking which results in a greater active metabolite generation [31] . Prasugrel undergoes less complex metabolization without involving CYP1A2 and therefore its efficacy should not be influenced by the smoking status [32] . However, a pharmacokinetic and pharmacodynamic study conducted by Gurbel et al. showed slightly stronger platelet inhibition by prasugrel in smokers than non-smokers. This study also confirmed stronger antiplatelet potency of clopidogrel amongst smokers [32] . Our results suggest that the antiplatelet effect of prasugrel is more stable in smokers.
Although the subgroup of low PR fluctuation in our study consisted exclusively of men, this may be by chance, since our study population comprised only 4 women. To draw any conclusions regarding the platelet response variability in relation to gender, a study with an adequate number of female participants should be conducted.
We observed PR less than 208 PRU in every platelet measurement performed during the study. The treatment with clopidogrel, a still widely used second generation P2Y12 receptor blocker, results in an inadequate platelet inhibition in approximately one-third of patients with ACS [33] . Newer third generation P2Y12 antagonists, such as prasugrel, showed more effective platelet inhibition [12, 34, 35] . In a study by Alexopoulos et al., 27 STEMI patients treated with prasugrel presented 11.5% HTPR 6 h after loading dose administration and 0% 5 days after the treatment initiation, as assessed with the VeryfyNow P2Y12 assay [36] . Similarly, in a study conducted by Laine et al. with 44 STEMI patients treated with prasugrel, HTPR measured 6-12 h after a loading dose of prasugrel and defined as VASP index above or equal to 50%, was reported in 4 patients (9,1%) [37] . Prasugrel was also shown to be effective in 44 ACS patients exhibiting HTPR following a clopidogrel loading dose. The rate of HTPR after 15 days of the maintenance treatment with prasugrel was only 2.4% in this high risk population [38] .
On the other hand, up to 80.9% of patients enrolled into our study presented PR < 30 PRU, a level which has been shown to increase the risk of bleeding complications [14] [15] [16] . Our results are consistent with the study conducted by Laine et al., with the latter showing a 63.6% incidence of LTPR (defined as VASP index ≤ 16%) measured 6 to 12 h after prasugrel loading dose administration [37] . A lower prevalence of LTPR (using the same VASP index ≤ 16% criterion), equal to 27.9% of patients, was reported by Bonello et al., with a concomitant 4.7-fold higher rate of bleeding events during a 1-year follow-up (15.6% v. 3.3%) [15] . In another study utilizing the VeryfyNow P2Y12 assay and the same cut-off point as in our study (< 30 PRU), the LTPR rate after 15 days of prasugrel treatment was 45.6% [39] .
More than one-third of our population had persistent LTPR (PR < 30 PRU in all three measurements). We believe that this subgroup of patients is of remarkably high risk of bleeding complications. Identifying such individuals and switching to less potent clopidogrel, as proposed by Kerneis et al., might be a reasonable option. However, this approach needs to be validated in large clinical trials as it may lead to ischemic events in clopidogrel non-responders [39] .
In our study, patients with persistent LTPR more often were smokers which seems to confirm the stable and high antiplatelet potency of prasugrel in tobacco users as discussed above. As expected, patients from this group tended to be younger, as advanced age is a known risk factor of HTPR [8, 27] .
Interestingly, patients with persistent LTPR presented a tendency for higher HDL cholesterol concentrations. Similar results regarding the association between clopidogrel resistance and lower HDL concentrations were reported for Jordanian and Serbian populations [26, 40] .
Limitations
Several limitations of our study should be acknowledged. Firstly, only one method of platelet function assessment was applied. Secondly, the study population size was small. Thirdly, the spectrum of data acquired by the researchers did not include some variables bearing potential impact on on-treatment platelet reactivity (e.g. inflammatory markers).
Conclusions
Our study showed relatively high inter-and intra-individual variability of platelet reactivity among patients in the stable phase of ACS, treated with a maintenance dose of prasugrel. Additionally, we pointed out high antiplatelet effectiveness of prasugrel, as all PR measurements were below the threshold indicating high thrombotic risk and two-thirds of the PR measurements were below the threshold of high bleeding risk. Active smoking might predispose to strong and stable on-prasugrel platelet inhibition.
